Drug Profile

GTX 201

Alternative Names: GTX-201

Latest Information Update: 29 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Oct 2024 Acasti Pharma is now called Grace Therapeutics
19 Oct 2024 Acasti Pharma Pipeline, October 2024: No updates; one specific indication dev line was already discontinued as not present on the current pipeline and unknown indication dev line is in active state for preclinical development
29 Aug 2024 Discontinued - Phase-I for Trigeminal neuralgia (unspecified route) (Acasti Pharma pipeline, August 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com